Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers.
Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.
In order to mitigate the challenges associated with ADC manufacturing, around 70-80% of the therapeutics developers prefer to outsource their operations to contract manufacturing organizations (CMOs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities.
To order this ~580 page report, which features 198+ figures and 198+ tables, please visit this link
Presently, more than 30 players claim to offer ADC contract manufacturing services
This segment of the industry is dominated by the presence of large (more than 501 employees) and mid-sized (51-500 employees) players, which collectively represent more than 80% of the total contract manufacturers in this domain. In addition, around15% firms were established post 2010.
More than 84 expansions were reported in this industry, during 2012-2021
Of the total, 57% instances were focused on enhancing dedicated capabilities and capacities, followed by those carried out for the expansion / establishment of manufacturing facilities (42%).
Partnership activity in this domain has increased at a CAGR of over 16%, during 2016- 2021
Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (18%), followed by product development agreements (16%) and research agreements (15%). Further, most of the deals were inked by players based in Europe (46%).
Global, installed ADC contract manufacturing capacity is currently estimated to be close to 33 Kilograms
The maximum share of the current installed capacity is expected to be captured by large players. Moreover, close to 37% of the installed manufacturing capacity is available in the Asia-Pacific region.
140,200+ patients have been enrolled in over 714 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, in the past three years. Of the total number of trials, close to 47% of the studies are recruiting patients, while 30% have been completed.
Global demand for ADC contract manufacturing is anticipated to grow at a CAGR of 13%, during 2022-2035
The commercial demand for ADC therapeutics is projected to increase at a CAGR of 22%. Further, the clinical demand for ADC therapeutics in phase III trials is projected to increase at a CAGR of 10%.
The market is anticipated to grow at a CAGR of nearly 13%, during the period 2022-2035
In terms of type of cancer, ADC therapeutics targeting solid tumors (48%) are anticipated to capture the highest share; this trend is unlikely to change in the foreseen future. Further, based on type of antibody isotype, majority of the revenue share (90%) of the overall market is likely to be driven by IgG1 antibodies.
To request a sample copy / brochure of this report, please visit link
The financial opportunity within the ADC contract market has been analyzed across the following segments:
While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
The opinions and insights presented in the report were also influenced by discussions held with key stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
The research also includes detailed profiles of key ADC contract manufacturers (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/adc-contract-manufacturing-market/218.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
